Drugs
Cancer Trials Guide Calls for Broader Eligibility, Flexible Dose Escalation
FDA is recommending less restrictive patient eligibility criteria and more flexible dose-escalation strategies in early-phase clinical trials for solid tumors, under a new draft guidance addressing common deficiencies identified during the agency's review of INDs. The draft guidance, Early-Phase IND Protocol Recommendations for Solid Tumors,